<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00395304</url>
  </required_header>
  <id_info>
    <org_study_id>444</org_study_id>
    <secondary_id>5U10HL064313</secondary_id>
    <secondary_id>5U10HL064288</secondary_id>
    <secondary_id>5U10HL064305</secondary_id>
    <secondary_id>5U10HL064295</secondary_id>
    <secondary_id>5U10HL064287</secondary_id>
    <secondary_id>5U10HL064307</secondary_id>
    <nct_id>NCT00395304</nct_id>
  </id_info>
  <brief_title>Childhood Asthma Research and Education (CARE) Network Trial - Best Add-On Therapy Giving Effective Response (BADGER)</brief_title>
  <acronym>BADGER</acronym>
  <official_title>Childhood Asthma Research and Education (CARE) Network Trial - Best Add-On Therapy Giving Effective Response (BADGER)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Milton S. Hershey Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Heart, Lung, and Blood Institute (NHLBI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Milton S. Hershey Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Asthma is a common, serious illness among children in the United States. While a low dose of
      inhaled corticosteroids (ICS) may effectively control symptoms, some children may require
      additional medications to maintain adequate asthma control. This study compares the
      effectiveness of a higher dose of ICS, ICS combined with a long-acting beta-agonist (LABA)
      medication, and ICS combined with a leukotriene receptor antagonist (LTRA) medication at
      reducing the impact and severity of asthma exacerbations that occur in children with mild to
      moderate persistent asthma.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Almost 9 million children in the United States have asthma, and it is a leading cause of
      hospitalizations and school absenteeism. Common asthma symptoms include wheezing, shortness
      of breath, chest tightness, and coughing. While there is no cure for asthma, most children
      who receive proper treatment are able to control symptoms and lead a normal life. Low doses
      of ICS are commonly prescribed to prevent symptoms and keep asthma under control. While this
      is usually sufficient to prevent asthma attacks, some children do not respond well to low
      dose ICS alone. For these children, their asthma symptoms may be more effectively controlled
      by either receiving a higher dose of ICS or receiving LABA or LTRA medications in combination
      with a low dose of ICS. Both LABA and LTRA medications are used to help control moderate to
      severe asthma. The purpose of this study is to compare the effectiveness of a high dose of
      ICS versus a low dose of ICS plus either LABA or LTRA medication at improving asthma control
      and reducing the severity of symptoms that occur in children with mild to moderate persistent
      asthma.

      This study began with an 8-week screening period during which participants were monitored
      while they used an inhaler with a low dose of ICS medication. During this time, participants
      also attended one or two study visits. At each visit, participants underwent a physical
      examination, exhaled nitric oxide analysis, and lung function and airway pressure testing.
      After enrollment criteria were met, participants underwent these same evaluations again, and
      they completed questionnaires to assess asthma control, quality of life, and home
      environmental factors. Blood was collected and a methacholine challenge test was completed,
      which artificially triggers an asthma attack to determine the severity of an individual's
      asthma. Participants then were randomly assigned to one of six treatment sequences, each of
      which includes the following three regimens in a different order:

        -  Low dose of ICS and salmeterol, a LABA medication

        -  Low dose of ICS and montelukast, a LTRA medication

        -  Double dose of ICS

      Each treatment period lasted 16 weeks, with study visits occurring weekly. A physical
      examination, blood collection, lung function and airway pressure testing, a methacholine
      challenge test, and questionnaires occurred at selected visits. Throughout the study,
      participants recorded asthma symptoms, peak expiratory flow rates, and rescue medication
      usage in a daily diary. The entire length of the study did not exceed 56 weeks.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2007</start_date>
  <completion_date type="Actual">December 2011</completion_date>
  <primary_completion_date type="Actual">December 2011</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The Number of Participants With a Differential Response to the Three Step-up Therapies Based on Fixed Threshold Criteria for the Following Three Asthma Control Measures: Use of Oral Prednisone for Acute Asthma Exacerbations, Asthma Control Days and FEV1.</measure>
    <time_frame>Measured during the last 12 weeks of each 16-week treatment period</time_frame>
    <description>One treatment period was ranked as better than another if the total amount of prednisone received during the period was at least 180 mg less, if the number of annualized asthma-control days during the final 12 weeks of the period was increased by at least 31 days, or if the FEV1 at the end of the period was at least 5% higher. If the prednisone threshold was met, then we ignored the number of asthmacontrol days and the FEV1. If the threshold for asthma-control days was met, then we ignored the FEV1. Otherwise, the order of response was determined by the FEV1.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in the Pre-bronchodilator Forced Expiratory Volume in One Second (FEV1) % Predicted</measure>
    <time_frame>Measured during the last 12 weeks of each 16-week treatment period</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in the Post-bronchodilator FEV1 Percent Predicted</measure>
    <time_frame>Measured during the last 12 weeks of each 16-week treatment period</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in the Pre-bronchodilator Forced Vital Capacity (FVC) % Predicted</measure>
    <time_frame>Measured during the last 12 weeks of each 16-week treatment period</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in the Pre-bronchodilator FEV1/FVC Ratio</measure>
    <time_frame>Measured during the last 12 weeks of each 16-week treatment period</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in the Morning Peak Expiratory Flow Rate (PEFR) % Predicted</measure>
    <time_frame>Measured during the last 12 weeks of each 16-week treatment period</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in the Evening Peak Expiratory Flow Rate (PEFR) % Predicted</measure>
    <time_frame>Measured during the last 12 weeks of each 16-week treatment period</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in the Peak Expiratory Flow Rate (PEFR) Variability</measure>
    <time_frame>Measured during the last 12 weeks of each 16-week treatment period</time_frame>
    <description>PEFR variability is calculated as 100% times the difference between the evening and morning PEFR values, divided by the average of the evening and morning PEFR values, i.e., PEFR variability = 100% x (morning PEFR - evening PEFR)/((morning PEFR + evening PEFR)/2)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in the Impulse Oscillometry Resistance at 5 Hertz</measure>
    <time_frame>Measured during the last 12 weeks of each 16-week treatment period</time_frame>
    <description>Change from baseline in the impulse oscillometry resistance at 5 Hertz, measured in kiloPascals per liters per second</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in the Logarithm Base 2 of the Methacholine PC20</measure>
    <time_frame>Measured during the last 12 weeks of each 16-week treatment period</time_frame>
    <description>The methacholine PC20 is the concentration of methacholine that causes a 20% decrease in the pre-bronchodilator FEV1. The logarithm base 2 transformation converts the PC20 into doubling dilutions.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in the Natural Logarithm of Exhaled Nitric Oxide (eNO)</measure>
    <time_frame>Measured during the last 12 weeks of each 16-week treatment period</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in the Asthma Control Test (ACT)</measure>
    <time_frame>Measured during the last 12 weeks of each 16-week treatment period</time_frame>
    <description>The ACT consists of five items, each scored as 1 (worst) to 5 (best). The five items are averaged.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Asthma Quality of Life</measure>
    <time_frame>Measured during the last 12 weeks of each 16-week treatment period</time_frame>
    <description>Asthma quality of life is measured as the average of 23 questions, each of which is scored from 1 (worse) to 7 (best)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Asthma Exacerbations</measure>
    <time_frame>Measured during the last 12 weeks of each 16-week treatment period</time_frame>
    <description>An asthma exacerbation was defined as the administration of a course of oral/systemic prednisone for the treatment of asthma.</description>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">182</enrollment>
  <condition>Asthma</condition>
  <arm_group>
    <arm_group_label>Sequence #1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>fluticasone propionate + montelukast, followed by fluticasone propionate, followed by fluticasone propionate + salmeterol</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sequence #2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>fluticasone propionate + montelukast, followed by fluticasone propionate + salmeterol, followed by followed by fluticasone propionate</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sequence #3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>fluticasone propionate + salmeterol, followed by fluticasone propionate, followed by fluticasone propionate + montelukast</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sequence #4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>fluticasone propionate + salmeterol, followed by fluticasone propionate + montelukast, followed by fluticasone propionate</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sequence #5</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>fluticasone propionate, followed by fluticasone propionate + salmeterol, followed by fluticasone propionate + montelukast</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sequence #6</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>fluticasone propionate, followed by fluticasone propionate + montelukast, followed by fluticasone propionate + salmeterol</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>fluticasone propionate + montelukast</intervention_name>
    <description>Dry-powder inhaler fluticasone 100 mcg bid (Flovent Diskus®, GlaxoSmithKline) plus Montelukast 5 or 10 mg qd (Singulair®, Merck)</description>
    <arm_group_label>Sequence #1</arm_group_label>
    <arm_group_label>Sequence #2</arm_group_label>
    <arm_group_label>Sequence #3</arm_group_label>
    <arm_group_label>Sequence #4</arm_group_label>
    <arm_group_label>Sequence #5</arm_group_label>
    <arm_group_label>Sequence #6</arm_group_label>
    <other_name>Flovent Diskus® + Singulair®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>fluticasone propionate</intervention_name>
    <description>Dry-powder inhaler fluticasone 250 mcg bid (Flovent Diskus®, GlaxoSmithKline)</description>
    <arm_group_label>Sequence #1</arm_group_label>
    <arm_group_label>Sequence #2</arm_group_label>
    <arm_group_label>Sequence #3</arm_group_label>
    <arm_group_label>Sequence #4</arm_group_label>
    <arm_group_label>Sequence #5</arm_group_label>
    <arm_group_label>Sequence #6</arm_group_label>
    <other_name>Flovent Diskus®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>fluticasone propionate + salmeterol</intervention_name>
    <description>Dry-powder inhaler fluticasone + salmeterol combination 100 mcg/50 mcg bid (Advair Diskus®, GlaxoSmithKline)</description>
    <arm_group_label>Sequence #1</arm_group_label>
    <arm_group_label>Sequence #2</arm_group_label>
    <arm_group_label>Sequence #3</arm_group_label>
    <arm_group_label>Sequence #4</arm_group_label>
    <arm_group_label>Sequence #5</arm_group_label>
    <arm_group_label>Sequence #6</arm_group_label>
    <other_name>Advair Diskus®</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Able to perform reproducible spirometry according to American Thoracic Society (ATS)
             criteria

          -  History of asthma symptoms (e.g., cough, wheezing, shortness of breath) and meets at
             least one of the following criteria:

               1. Naïve to controller therapy and meeting National Asthma Education and Prevention
                  Program (NAEPP) criteria for mild-moderate persistent asthma (symptoms at least 2
                  days per week and/or night-time awakenings due to asthma at least 2 nights per
                  month)

               2. Current uncontrolled asthma (meets NAEPP criteria for mild-moderate persistent
                  asthma) while receiving an ICS dose greater than or equal to 200 ug per day of
                  fluticasone equivalent or some form of non-ICS controller therapy (e.g.,
                  montelukast, theophylline, cromolyn)

               3. Asthma is currently under control while receiving an ICS dose between 300 to 400
                  ug per day of fluticasone equivalent and willing to consider changing current
                  treatment to monotherapy with one dose of ICS (current standard of care)

               4. Asthma is currently under control while receiving some form of combination
                  therapy, such as ICS less than or equal to 200 ug per day of fluticasone
                  equivalent in addition to a non-ICS controller therapy (e.g., LABA, montelukast,
                  theophylline, cromolyn), and willing to consider changing current treatment to
                  monotherapy with one dose of ICS (current standard of care)

          -  FEV1 reversibility of at least 12% following bronchodilator administration (4 puffs)
             at study visit 1. Individuals will need to hold albuterol, montelukast, theophylline,
             ipratropium bromide (or other anticholinergics) and LABAs per study instructions prior
             to reversibility testing. If an individual is receiving these types of medications
             prior to study visit 1, he/she may be brought back to the clinical center within 1
             week following appropriate medication withholding to attempt qualification by
             reversibility criteria. If the individual does not meet this requirement, they may
             qualify for enrollment if their PC20 methacholine FEV1 is less than or equal to 12.5
             mg/ml at the time of randomization. If FEV1 is less than 70%, thus precluding the
             methacholine challenge at this visit, then completion of the visit will be postponed
             several days and an additional attempt to obtain a methacholine challenge test will be
             made. If the methacholine challenge still cannot be performed, an individual may still
             qualify by reversibility criteria at this visit.

          -  History of clinical varicella or varicella vaccine; individuals needing the vaccine
             may receive it from their primary care physician prior to study entry

          -  Ability of parent to provide informed consent; verbal assent must be obtained from
             children less than 7 years of age and written assent must be obtained from children
             between 7 and 18 years of age

          -  If female, willing to use an effective form of contraception

        Prior to being randomly assigned to a treatment group, participants must meet the following
        criteria to remain in the study:

          -  Lack of acceptable asthma control during the 8-week screening period as defined by the
             following criteria:

             1) On average, on more than 2 days per week, one or all of the following:

               1. Diary-reported symptoms

               2. The use of inhaled bronchodilator (not including pre-exercise)

               3. Peak flows in the yellow zone (less than 80% of post bronchodilator PEF value
                  obtained at study visit 1) OR

          -  On average, more than 1 night-time awakening due to asthma, during each 2-week period

        Exclusion Criteria:

          -  Corticosteroid treatment for any condition prior to study entry within the following
             defined timepoints:

               1. Oral - Use within 2 weeks of the screening visit

               2. Injectable - Use within 2 weeks of the screening visit

               3. Nasal - May be used at any time during the study at the discretion of the study
                  investigator or primary care physician

          -  Current or prior use of medications known to significantly interact with
             corticosteroid disposition (within a 2-week period of study visit 1), including but
             not limited to carbamazepine, erythromycin or other macrolide antibiotics,
             phenobarbital, phenytoin, rifampin, or ketoconazole

          -  Pre-bronchodilator FEV1 less than 60% predicted at study visit 1

          -  More than three hospitalizations for asthma in the year prior to study entry

          -  Presence of chronic or active lung disease other than asthma

          -  Significant medical illness other than asthma, including thyroid disease, diabetes
             mellitus, Cushing's disease, Addison's disease, hepatic disease, or concurrent medical
             problems that could require oral corticosteroids during the study or would place the
             participant at increased risk while participating in the study

          -  History of cataracts, glaucoma, or any other medical disorder associated with an
             adverse effect to corticosteroids

          -  Gastroesophageal reflux symptoms not controlled by standard medical therapy

          -  History of significant asthma exacerbation within 2 weeks of study visit 1 or more
             than 5 courses of systemic corticosteroids in the year prior to study entry

          -  History of a life-threatening asthma exacerbation requiring intubation, mechanical
             ventilation, or resulting in a hypoxic seizure within the 5 years prior to study entry

          -  History of adverse reactions to ICS, LTRA, or LABA preparations or any of their
             ingredients

          -  Receiving hyposensitization therapy other than an established maintenance regimen
             (i.e., continuous regimen for at least 3 months prior to study entry)

          -  Pregnant or breastfeeding

          -  Inability to perform study procedures

          -  Refusal to consent to a genotype evaluation

          -  Inability of the child to ingest the study drug

          -  Cigarette smoking or smokeless tobacco use in the year prior to study entry

          -  Current participation or participation in the month prior to study entry in another
             investigational drug trial

          -  Evidence that the family may be unreliable or nonadherent, or may move from the
             clinical center area before study completion
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Years</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David T. Mauger, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Penn State College of Medicine</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Stanley J. Szefler, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Jewish Health</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Robert F. Lemanske, Jr., MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Wisconsin, Madison</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Robert S. Zeiger, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Kaiser Permanente Medical Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Robert C. Strunk, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Washington University School of Medicine</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Fernando D. Martinez, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Arizona College of Medicine</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Lynn M. Taussig, MD</last_name>
    <role>Study Chair</role>
    <affiliation>University of Denver</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Arizona College of Medicine</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85724</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kaiser Permanente Medical Center</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92111</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Jewish Medical and Research Center</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80206</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Washington University School of Medicine</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Wisconsin - Madison</name>
      <address>
        <city>Madison</city>
        <state>Wisconsin</state>
        <zip>53792</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.asthma-carenet.org</url>
    <description>Click here for the Childhood Asthma Research and Education (CARE) Network web site</description>
  </link>
  <results_reference>
    <citation>Lemanske RF Jr, Mauger DT, Sorkness CA, Jackson DJ, Boehmer SJ, Martinez FD, Strunk RC, Szefler SJ, Zeiger RS, Bacharier LB, Covar RA, Guilbert TW, Larsen G, Morgan WJ, Moss MH, Spahn JD, Taussig LM; Childhood Asthma Research and Education (CARE) Network of the National Heart, Lung, and Blood Institute. Step-up therapy for children with uncontrolled asthma receiving inhaled corticosteroids. N Engl J Med. 2010 Mar 18;362(11):975-85. doi: 10.1056/NEJMoa1001278. Epub 2010 Mar 2.</citation>
    <PMID>20197425</PMID>
  </results_reference>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 31, 2006</study_first_submitted>
  <study_first_submitted_qc>November 1, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 2, 2006</study_first_posted>
  <results_first_submitted>May 17, 2010</results_first_submitted>
  <results_first_submitted_qc>August 23, 2010</results_first_submitted_qc>
  <results_first_posted type="Estimate">September 17, 2010</results_first_posted>
  <last_update_submitted>March 25, 2018</last_update_submitted>
  <last_update_submitted_qc>March 25, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 25, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Milton S. Hershey Medical Center</investigator_affiliation>
    <investigator_full_name>Vernon M. Chinchilli, PhD</investigator_full_name>
    <investigator_title>Professor and Chair, Department of Public Health Sciences</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Asthma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fluticasone</mesh_term>
    <mesh_term>Salmeterol Xinafoate</mesh_term>
    <mesh_term>Fluticasone Propionate, Salmeterol Xinafoate Drug Combination</mesh_term>
    <mesh_term>Montelukast</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>2xICS, 1xICS + LABA, 1xICS + LTRA</title>
          <description>Dry-powder inhaler fluticasone 250 mcg bid (Flovent Diskus®, GlaxoSmithKline), followed by Dry-powder inhaler fluticasone + salmeterol combination 100 mcg/50 mcg bid (Advair Diskus®, GlaxoSmithKline), followed by Dry-powder inhaler fluticasone 100 mcg bid (Flovent Diskus®, GlaxoSmithKline) plus Montelukast 5 or 10 mg qd (Singulair®, Merck)</description>
        </group>
        <group group_id="P2">
          <title>2xICS, 1xICS + LTRA, 1xICS + LABA</title>
          <description>Dry-powder inhaler fluticasone 250 mcg bid (Flovent Diskus®, GlaxoSmithKline), followed by Dry-powder inhaler fluticasone 100 mcg bid (Flovent Diskus®, GlaxoSmithKline) plus Montelukast 5 or 10 mg qd (Singulair®, Merck), followed by Dry-powder inhaler fluticasone + salmeterol combination 100 mcg/50 mcg bid (Advair Diskus®, GlaxoSmithKline)</description>
        </group>
        <group group_id="P3">
          <title>1xICS +LABA, 2xICS, 1xICS + LTRA</title>
          <description>Dry-powder inhaler fluticasone + salmeterol combination 100 mcg/50 mcg bid (Advair Diskus®, GlaxoSmithKline), followed by Dry-powder inhaler fluticasone 250 mcg bid (Flovent Diskus®, GlaxoSmithKline), followed by Dry-powder inhaler fluticasone 100 mcg bid (Flovent Diskus®, GlaxoSmithKline) plus Montelukast 5 or 10 mg qd (Singulair®, Merck)</description>
        </group>
        <group group_id="P4">
          <title>1xICS + LABA, 1xICS + LTRA, 2xICS</title>
          <description>Dry-powder inhaler fluticasone + salmeterol combination 100 mcg/50 mcg bid (Advair Diskus®, GlaxoSmithKline), followed by Dry-powder inhaler fluticasone 100 mcg bid (Flovent Diskus®, GlaxoSmithKline) plus Montelukast 5 or 10 mg qd (Singulair®, Merck), followed by Dry-powder inhaler fluticasone 250 mcg bid (Flovent Diskus®, GlaxoSmithKline)</description>
        </group>
        <group group_id="P5">
          <title>1xICS + LTRA, 2xICS, 1xICS + LABA</title>
          <description>Dry-powder inhaler fluticasone 100 mcg bid (Flovent Diskus®, GlaxoSmithKline) plus Montelukast 5 or 10 mg qd (Singulair®, Merck), followed by Dry-powder inhaler fluticasone 250 mcg bid (Flovent Diskus®, GlaxoSmithKline), followed by Dry-powder inhaler fluticasone + salmeterol combination 100 mcg/50 mcg bid (Advair Diskus®, GlaxoSmithKline)</description>
        </group>
        <group group_id="P6">
          <title>1xICS + LTRA, 1xICS + LABA, 2xICS</title>
          <description>Dry-powder inhaler fluticasone 100 mcg bid (Flovent Diskus®, GlaxoSmithKline) plus Montelukast 5 or 10 mg qd (Singulair®, Merck), followed by Dry-powder inhaler fluticasone + salmeterol combination 100 mcg/50 mcg bid (Advair Diskus®, GlaxoSmithKline), followed by Dry-powder inhaler fluticasone 250 mcg bid (Flovent Diskus®, GlaxoSmithKline)</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Treatment Period 1</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="31"/>
                <participants group_id="P2" count="30"/>
                <participants group_id="P3" count="30"/>
                <participants group_id="P4" count="31"/>
                <participants group_id="P5" count="28"/>
                <participants group_id="P6" count="32"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="30"/>
                <participants group_id="P2" count="26"/>
                <participants group_id="P3" count="30"/>
                <participants group_id="P4" count="28"/>
                <participants group_id="P5" count="27"/>
                <participants group_id="P6" count="30"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="3"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="2"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Treatment Period 2</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="30"/>
                <participants group_id="P2" count="26"/>
                <participants group_id="P3" count="30"/>
                <participants group_id="P4" count="28"/>
                <participants group_id="P5" count="27"/>
                <participants group_id="P6" count="30"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="30"/>
                <participants group_id="P2" count="22"/>
                <participants group_id="P3" count="29"/>
                <participants group_id="P4" count="27"/>
                <participants group_id="P5" count="27"/>
                <participants group_id="P6" count="28"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Treatment Period 3</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="30"/>
                <participants group_id="P2" count="22"/>
                <participants group_id="P3" count="29"/>
                <participants group_id="P4" count="27"/>
                <participants group_id="P5" count="27"/>
                <participants group_id="P6" count="28"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="29"/>
                <participants group_id="P2" count="20"/>
                <participants group_id="P3" count="29"/>
                <participants group_id="P4" count="25"/>
                <participants group_id="P5" count="27"/>
                <participants group_id="P6" count="27"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="2"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>All Participants</title>
          <description>All participants randomized to the six crossover sequences</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="182"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="182"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10.8" spread="2.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="63"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="119"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="182"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>The Number of Participants With a Differential Response to the Three Step-up Therapies Based on Fixed Threshold Criteria for the Following Three Asthma Control Measures: Use of Oral Prednisone for Acute Asthma Exacerbations, Asthma Control Days and FEV1.</title>
        <description>One treatment period was ranked as better than another if the total amount of prednisone received during the period was at least 180 mg less, if the number of annualized asthma-control days during the final 12 weeks of the period was increased by at least 31 days, or if the FEV1 at the end of the period was at least 5% higher. If the prednisone threshold was met, then we ignored the number of asthmacontrol days and the FEV1. If the threshold for asthma-control days was met, then we ignored the FEV1. Otherwise, the order of response was determined by the FEV1.</description>
        <time_frame>Measured during the last 12 weeks of each 16-week treatment period</time_frame>
        <population>ITT. Although only 157 participants completed all three treatment periods, there was sufficient data on 8 additional participants to include them in the analysis of the primary outcome.</population>
        <group_list>
          <group group_id="O1">
            <title>All Participants</title>
            <description>All participants randomized to the six crossover sequences</description>
          </group>
        </group_list>
        <measure>
          <title>The Number of Participants With a Differential Response to the Three Step-up Therapies Based on Fixed Threshold Criteria for the Following Three Asthma Control Measures: Use of Oral Prednisone for Acute Asthma Exacerbations, Asthma Control Days and FEV1.</title>
          <description>One treatment period was ranked as better than another if the total amount of prednisone received during the period was at least 180 mg less, if the number of annualized asthma-control days during the final 12 weeks of the period was increased by at least 31 days, or if the FEV1 at the end of the period was at least 5% higher. If the prednisone threshold was met, then we ignored the number of asthmacontrol days and the FEV1. If the threshold for asthma-control days was met, then we ignored the FEV1. Otherwise, the order of response was determined by the FEV1.</description>
          <population>ITT. Although only 157 participants completed all three treatment periods, there was sufficient data on 8 additional participants to include them in the analysis of the primary outcome.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="165"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="161"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in the Pre-bronchodilator Forced Expiratory Volume in One Second (FEV1) % Predicted</title>
        <time_frame>Measured during the last 12 weeks of each 16-week treatment period</time_frame>
        <population>Patients who completed the 16-week treatment period for the specific treatment (2xICS, 1xICS + LABA, or 1xICS + LTRA) within the three-way crossover design</population>
        <group_list>
          <group group_id="O1">
            <title>2xICS</title>
            <description>Dry-powder inhaler fluticasone 250 mcg bid (Flovent Diskus®, GlaxoSmithKline)</description>
          </group>
          <group group_id="O2">
            <title>1xICS + LABA</title>
            <description>Dry-powder inhaler fluticasone + salmeterol combination 100 mcg/50 mcg bid (Advair Diskus®, GlaxoSmithKline)</description>
          </group>
          <group group_id="O3">
            <title>1xICS + LTRA</title>
            <description>Dry-powder inhaler fluticasone 100 mcg bid (Flovent Diskus®, GlaxoSmithKline) plus Montelukast 5 or 10 mg qd (Singulair®, Merck)</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in the Pre-bronchodilator Forced Expiratory Volume in One Second (FEV1) % Predicted</title>
          <population>Patients who completed the 16-week treatment period for the specific treatment (2xICS, 1xICS + LABA, or 1xICS + LTRA) within the three-way crossover design</population>
          <units>percentage points</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="161"/>
                <count group_id="O2" value="160"/>
                <count group_id="O3" value="155"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.26" spread="11.02"/>
                    <measurement group_id="O2" value="1.07" spread="9.45"/>
                    <measurement group_id="O3" value="-0.84" spread="10.25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in the Post-bronchodilator FEV1 Percent Predicted</title>
        <time_frame>Measured during the last 12 weeks of each 16-week treatment period</time_frame>
        <population>Patients who completed the 16-week treatment period for the specific treatment (2xICS, 1xICS + LABA, or 1xICS + LTRA) within the three-way crossover design</population>
        <group_list>
          <group group_id="O1">
            <title>2xICS</title>
            <description>Dry-powder inhaler fluticasone 250 mcg bid (Flovent Diskus®, GlaxoSmithKline)</description>
          </group>
          <group group_id="O2">
            <title>1xICS + LABA</title>
            <description>Dry-powder inhaler fluticasone + salmeterol combination 100 mcg/50 mcg bid (Advair Diskus®, GlaxoSmithKline)</description>
          </group>
          <group group_id="O3">
            <title>1xICS + LTRA</title>
            <description>Dry-powder inhaler fluticasone 100 mcg bid (Flovent Diskus®, GlaxoSmithKline) plus Montelukast 5 or 10 mg qd (Singulair®, Merck)</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in the Post-bronchodilator FEV1 Percent Predicted</title>
          <population>Patients who completed the 16-week treatment period for the specific treatment (2xICS, 1xICS + LABA, or 1xICS + LTRA) within the three-way crossover design</population>
          <units>percentage points</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="157"/>
                <count group_id="O2" value="152"/>
                <count group_id="O3" value="153"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.2" spread="9.7"/>
                    <measurement group_id="O2" value="-1.2" spread="8.9"/>
                    <measurement group_id="O3" value="-0.8" spread="10.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in the Pre-bronchodilator Forced Vital Capacity (FVC) % Predicted</title>
        <time_frame>Measured during the last 12 weeks of each 16-week treatment period</time_frame>
        <population>Patients who completed the 16-week treatment period for the specific treatment (2xICS, 1xICS + LABA, or 1xICS + LTRA) within the three-way crossover design</population>
        <group_list>
          <group group_id="O1">
            <title>2xICS</title>
            <description>Dry-powder inhaler fluticasone 250 mcg bid (Flovent Diskus®, GlaxoSmithKline)</description>
          </group>
          <group group_id="O2">
            <title>1xICS + LABA</title>
            <description>Dry-powder inhaler fluticasone + salmeterol combination 100 mcg/50 mcg bid (Advair Diskus®, GlaxoSmithKline)</description>
          </group>
          <group group_id="O3">
            <title>1xICS + LTRA</title>
            <description>Dry-powder inhaler fluticasone 100 mcg bid (Flovent Diskus®, GlaxoSmithKline) plus Montelukast 5 or 10 mg qd (Singulair®, Merck)</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in the Pre-bronchodilator Forced Vital Capacity (FVC) % Predicted</title>
          <population>Patients who completed the 16-week treatment period for the specific treatment (2xICS, 1xICS + LABA, or 1xICS + LTRA) within the three-way crossover design</population>
          <units>percentage points</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="161"/>
                <count group_id="O2" value="160"/>
                <count group_id="O3" value="155"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.00" spread="10.18"/>
                    <measurement group_id="O2" value="-1.58" spread="8.04"/>
                    <measurement group_id="O3" value="-1.56" spread="8.63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in the Pre-bronchodilator FEV1/FVC Ratio</title>
        <time_frame>Measured during the last 12 weeks of each 16-week treatment period</time_frame>
        <population>Patients who completed the 16-week treatment period for the specific treatment (2xICS, 1xICS + LABA, or 1xICS + LTRA) within the three-way crossover design</population>
        <group_list>
          <group group_id="O1">
            <title>2xICS</title>
            <description>Dry-powder inhaler fluticasone 250 mcg bid (Flovent Diskus®, GlaxoSmithKline)</description>
          </group>
          <group group_id="O2">
            <title>1xICS + LABA</title>
            <description>Dry-powder inhaler fluticasone + salmeterol combination 100 mcg/50 mcg bid (Advair Diskus®, GlaxoSmithKline)</description>
          </group>
          <group group_id="O3">
            <title>1xICS + LTRA</title>
            <description>Dry-powder inhaler fluticasone 100 mcg bid (Flovent Diskus®, GlaxoSmithKline) plus Montelukast 5 or 10 mg qd (Singulair®, Merck)</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in the Pre-bronchodilator FEV1/FVC Ratio</title>
          <population>Patients who completed the 16-week treatment period for the specific treatment (2xICS, 1xICS + LABA, or 1xICS + LTRA) within the three-way crossover design</population>
          <units>ratio</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="161"/>
                <count group_id="O2" value="160"/>
                <count group_id="O3" value="155"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.98" spread="4.60"/>
                    <measurement group_id="O2" value="2.13" spread="4.75"/>
                    <measurement group_id="O3" value="0.55" spread="5.11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in the Morning Peak Expiratory Flow Rate (PEFR) % Predicted</title>
        <time_frame>Measured during the last 12 weeks of each 16-week treatment period</time_frame>
        <population>Patients who completed the 16-week treatment period for the specific treatment (2xICS, 1xICS + LABA, or 1xICS + LTRA) within the three-way crossover design</population>
        <group_list>
          <group group_id="O1">
            <title>2xICS</title>
            <description>Dry-powder inhaler fluticasone 250 mcg bid (Flovent Diskus®, GlaxoSmithKline)</description>
          </group>
          <group group_id="O2">
            <title>1xICS + LABA</title>
            <description>Dry-powder inhaler fluticasone + salmeterol combination 100 mcg/50 mcg bid (Advair Diskus®, GlaxoSmithKline)</description>
          </group>
          <group group_id="O3">
            <title>1xICS + LTRA</title>
            <description>Dry-powder inhaler fluticasone 100 mcg bid (Flovent Diskus®, GlaxoSmithKline) plus Montelukast 5 or 10 mg qd (Singulair®, Merck)</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in the Morning Peak Expiratory Flow Rate (PEFR) % Predicted</title>
          <population>Patients who completed the 16-week treatment period for the specific treatment (2xICS, 1xICS + LABA, or 1xICS + LTRA) within the three-way crossover design</population>
          <units>percentage points</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="159"/>
                <count group_id="O2" value="161"/>
                <count group_id="O3" value="155"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.44" spread="11.25"/>
                    <measurement group_id="O2" value="6.26" spread="9.91"/>
                    <measurement group_id="O3" value="4.04" spread="9.66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in the Evening Peak Expiratory Flow Rate (PEFR) % Predicted</title>
        <time_frame>Measured during the last 12 weeks of each 16-week treatment period</time_frame>
        <population>Patients who completed the 16-week treatment period for the specific treatment (2xICS, 1xICS + LABA, or 1xICS + LTRA) within the three-way crossover design</population>
        <group_list>
          <group group_id="O1">
            <title>2xICS</title>
            <description>Dry-powder inhaler fluticasone 250 mcg bid (Flovent Diskus®, GlaxoSmithKline)</description>
          </group>
          <group group_id="O2">
            <title>1xICS + LABA</title>
            <description>Dry-powder inhaler fluticasone + salmeterol combination 100 mcg/50 mcg bid (Advair Diskus®, GlaxoSmithKline)</description>
          </group>
          <group group_id="O3">
            <title>1xICS + LTRA</title>
            <description>Dry-powder inhaler fluticasone 100 mcg bid (Flovent Diskus®, GlaxoSmithKline) plus Montelukast 5 or 10 mg qd (Singulair®, Merck)</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in the Evening Peak Expiratory Flow Rate (PEFR) % Predicted</title>
          <population>Patients who completed the 16-week treatment period for the specific treatment (2xICS, 1xICS + LABA, or 1xICS + LTRA) within the three-way crossover design</population>
          <units>percentage points</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="159"/>
                <count group_id="O2" value="161"/>
                <count group_id="O3" value="155"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.84" spread="10.17"/>
                    <measurement group_id="O2" value="4.87" spread="9.20"/>
                    <measurement group_id="O3" value="2.29" spread="8.73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in the Peak Expiratory Flow Rate (PEFR) Variability</title>
        <description>PEFR variability is calculated as 100% times the difference between the evening and morning PEFR values, divided by the average of the evening and morning PEFR values, i.e., PEFR variability = 100% x (morning PEFR - evening PEFR)/((morning PEFR + evening PEFR)/2)</description>
        <time_frame>Measured during the last 12 weeks of each 16-week treatment period</time_frame>
        <population>Patients who completed the 16-week treatment period for the specific treatment (2xICS, 1xICS + LABA, or 1xICS + LTRA) within the three-way crossover design</population>
        <group_list>
          <group group_id="O1">
            <title>2xICS</title>
            <description>Dry-powder inhaler fluticasone 250 mcg bid (Flovent Diskus®, GlaxoSmithKline)</description>
          </group>
          <group group_id="O2">
            <title>1xICS + LABA</title>
            <description>Dry-powder inhaler fluticasone + salmeterol combination 100 mcg/50 mcg bid (Advair Diskus®, GlaxoSmithKline)</description>
          </group>
          <group group_id="O3">
            <title>1xICS + LTRA</title>
            <description>Dry-powder inhaler fluticasone 100 mcg bid (Flovent Diskus®, GlaxoSmithKline) plus Montelukast 5 or 10 mg qd (Singulair®, Merck)</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in the Peak Expiratory Flow Rate (PEFR) Variability</title>
          <description>PEFR variability is calculated as 100% times the difference between the evening and morning PEFR values, divided by the average of the evening and morning PEFR values, i.e., PEFR variability = 100% x (morning PEFR - evening PEFR)/((morning PEFR + evening PEFR)/2)</description>
          <population>Patients who completed the 16-week treatment period for the specific treatment (2xICS, 1xICS + LABA, or 1xICS + LTRA) within the three-way crossover design</population>
          <units>percentage points</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="154"/>
                <count group_id="O2" value="156"/>
                <count group_id="O3" value="150"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.09" spread="7.37"/>
                    <measurement group_id="O2" value="1.61" spread="6.83"/>
                    <measurement group_id="O3" value="1.72" spread="6.68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in the Impulse Oscillometry Resistance at 5 Hertz</title>
        <description>Change from baseline in the impulse oscillometry resistance at 5 Hertz, measured in kiloPascals per liters per second</description>
        <time_frame>Measured during the last 12 weeks of each 16-week treatment period</time_frame>
        <population>Patients who completed the 16-week treatment period for the specific treatment (2xICS, 1xICS + LABA, or 1xICS + LTRA) within the three-way crossover design</population>
        <group_list>
          <group group_id="O1">
            <title>2xICS</title>
            <description>Dry-powder inhaler fluticasone 250 mcg bid (Flovent Diskus®, GlaxoSmithKline)</description>
          </group>
          <group group_id="O2">
            <title>1xICS + LABA</title>
            <description>Dry-powder inhaler fluticasone + salmeterol combination 100 mcg/50 mcg bid (Advair Diskus®, GlaxoSmithKline)</description>
          </group>
          <group group_id="O3">
            <title>1xICS + LTRA</title>
            <description>Dry-powder inhaler fluticasone 100 mcg bid (Flovent Diskus®, GlaxoSmithKline) plus Montelukast 5 or 10 mg qd (Singulair®, Merck)</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in the Impulse Oscillometry Resistance at 5 Hertz</title>
          <description>Change from baseline in the impulse oscillometry resistance at 5 Hertz, measured in kiloPascals per liters per second</description>
          <population>Patients who completed the 16-week treatment period for the specific treatment (2xICS, 1xICS + LABA, or 1xICS + LTRA) within the three-way crossover design</population>
          <units>kiloPascals per liters per second</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="165"/>
                <count group_id="O2" value="163"/>
                <count group_id="O3" value="161"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.08" spread="0.15"/>
                    <measurement group_id="O2" value="-0.09" spread="0.13"/>
                    <measurement group_id="O3" value="-0.06" spread="0.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in the Logarithm Base 2 of the Methacholine PC20</title>
        <description>The methacholine PC20 is the concentration of methacholine that causes a 20% decrease in the pre-bronchodilator FEV1. The logarithm base 2 transformation converts the PC20 into doubling dilutions.</description>
        <time_frame>Measured during the last 12 weeks of each 16-week treatment period</time_frame>
        <population>Patients who completed the 16-week treatment period for the specific treatment (2xICS, 1xICS + LABA, or 1xICS + LTRA) within the three-way crossover design</population>
        <group_list>
          <group group_id="O1">
            <title>2xICS</title>
            <description>Dry-powder inhaler fluticasone 250 mcg bid (Flovent Diskus®, GlaxoSmithKline)</description>
          </group>
          <group group_id="O2">
            <title>1xICS + LABA</title>
            <description>Dry-powder inhaler fluticasone + salmeterol combination 100 mcg/50 mcg bid (Advair Diskus®, GlaxoSmithKline)</description>
          </group>
          <group group_id="O3">
            <title>1xICS + LTRA</title>
            <description>Dry-powder inhaler fluticasone 100 mcg bid (Flovent Diskus®, GlaxoSmithKline) plus Montelukast 5 or 10 mg qd (Singulair®, Merck)</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in the Logarithm Base 2 of the Methacholine PC20</title>
          <description>The methacholine PC20 is the concentration of methacholine that causes a 20% decrease in the pre-bronchodilator FEV1. The logarithm base 2 transformation converts the PC20 into doubling dilutions.</description>
          <population>Patients who completed the 16-week treatment period for the specific treatment (2xICS, 1xICS + LABA, or 1xICS + LTRA) within the three-way crossover design</population>
          <units>doubling dilutions</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="111"/>
                <count group_id="O2" value="112"/>
                <count group_id="O3" value="94"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.11" spread="2.14"/>
                    <measurement group_id="O2" value="1.20" spread="2.31"/>
                    <measurement group_id="O3" value="1.00" spread="2.16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in the Natural Logarithm of Exhaled Nitric Oxide (eNO)</title>
        <time_frame>Measured during the last 12 weeks of each 16-week treatment period</time_frame>
        <population>Patients who completed the 16-week treatment period for the specific treatment (2xICS, 1xICS + LABA, or 1xICS + LTRA) within the three-way crossover design</population>
        <group_list>
          <group group_id="O1">
            <title>2xICS</title>
            <description>Dry-powder inhaler fluticasone 250 mcg bid (Flovent Diskus®, GlaxoSmithKline)</description>
          </group>
          <group group_id="O2">
            <title>1xICS + LABA</title>
            <description>Dry-powder inhaler fluticasone + salmeterol combination 100 mcg/50 mcg bid (Advair Diskus®, GlaxoSmithKline)</description>
          </group>
          <group group_id="O3">
            <title>1xICS + LTRA</title>
            <description>Dry-powder inhaler fluticasone 100 mcg bid (Flovent Diskus®, GlaxoSmithKline) plus Montelukast 5 or 10 mg qd (Singulair®, Merck)</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in the Natural Logarithm of Exhaled Nitric Oxide (eNO)</title>
          <population>Patients who completed the 16-week treatment period for the specific treatment (2xICS, 1xICS + LABA, or 1xICS + LTRA) within the three-way crossover design</population>
          <units>natural logarithm of parts per billion</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="151"/>
                <count group_id="O2" value="150"/>
                <count group_id="O3" value="150"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.04" spread="0.68"/>
                    <measurement group_id="O2" value="-0.05" spread="0.74"/>
                    <measurement group_id="O3" value="-0.02" spread="0.71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in the Asthma Control Test (ACT)</title>
        <description>The ACT consists of five items, each scored as 1 (worst) to 5 (best). The five items are averaged.</description>
        <time_frame>Measured during the last 12 weeks of each 16-week treatment period</time_frame>
        <population>Patients who completed the 16-week treatment period for the specific treatment (2xICS, 1xICS + LABA, or 1xICS + LTRA) within the three-way crossover design</population>
        <group_list>
          <group group_id="O1">
            <title>2xICS</title>
            <description>Dry-powder inhaler fluticasone 250 mcg bid (Flovent Diskus®, GlaxoSmithKline)</description>
          </group>
          <group group_id="O2">
            <title>1xICS + LABA</title>
            <description>Dry-powder inhaler fluticasone + salmeterol combination 100 mcg/50 mcg bid (Advair Diskus®, GlaxoSmithKline)</description>
          </group>
          <group group_id="O3">
            <title>1xICS + LTRA</title>
            <description>Dry-powder inhaler fluticasone 100 mcg bid (Flovent Diskus®, GlaxoSmithKline) plus Montelukast 5 or 10 mg qd (Singulair®, Merck)</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in the Asthma Control Test (ACT)</title>
          <description>The ACT consists of five items, each scored as 1 (worst) to 5 (best). The five items are averaged.</description>
          <population>Patients who completed the 16-week treatment period for the specific treatment (2xICS, 1xICS + LABA, or 1xICS + LTRA) within the three-way crossover design</population>
          <units>units on a scale (1, 2, 3, 4, 5)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="164"/>
                <count group_id="O2" value="162"/>
                <count group_id="O3" value="159"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.49" spread="4.09"/>
                    <measurement group_id="O2" value="1.87" spread="4.12"/>
                    <measurement group_id="O3" value="1.69" spread="4.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Asthma Quality of Life</title>
        <description>Asthma quality of life is measured as the average of 23 questions, each of which is scored from 1 (worse) to 7 (best)</description>
        <time_frame>Measured during the last 12 weeks of each 16-week treatment period</time_frame>
        <population>Patients who completed the 16-week treatment period for the specific treatment (2xICS, 1xICS + LABA, or 1xICS + LTRA) within the three-way crossover design</population>
        <group_list>
          <group group_id="O1">
            <title>2xICS</title>
            <description>Dry-powder inhaler fluticasone 250 mcg bid (Flovent Diskus®, GlaxoSmithKline)</description>
          </group>
          <group group_id="O2">
            <title>1xICS + LABA</title>
            <description>Dry-powder inhaler fluticasone + salmeterol combination 100 mcg/50 mcg bid (Advair Diskus®, GlaxoSmithKline)</description>
          </group>
          <group group_id="O3">
            <title>1xICS + LTRA</title>
            <description>Dry-powder inhaler fluticasone 100 mcg bid (Flovent Diskus®, GlaxoSmithKline) plus Montelukast 5 or 10 mg qd (Singulair®, Merck)</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Asthma Quality of Life</title>
          <description>Asthma quality of life is measured as the average of 23 questions, each of which is scored from 1 (worse) to 7 (best)</description>
          <population>Patients who completed the 16-week treatment period for the specific treatment (2xICS, 1xICS + LABA, or 1xICS + LTRA) within the three-way crossover design</population>
          <units>units on a scale (1 through 7)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="165"/>
                <count group_id="O2" value="161"/>
                <count group_id="O3" value="160"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.2" spread="0.1"/>
                    <measurement group_id="O2" value="0.3" spread="0.9"/>
                    <measurement group_id="O3" value="0.3" spread="1.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Asthma Exacerbations</title>
        <description>An asthma exacerbation was defined as the administration of a course of oral/systemic prednisone for the treatment of asthma.</description>
        <time_frame>Measured during the last 12 weeks of each 16-week treatment period</time_frame>
        <population>Patients who completed the 16-week treatment period for the specific treatment (2xICS, 1xICS + LABA, or 1xICS + LTRA) within the three-way crossover design</population>
        <group_list>
          <group group_id="O1">
            <title>2xICS</title>
            <description>Dry-powder inhaler fluticasone 250 mcg bid (Flovent Diskus®, GlaxoSmithKline)</description>
          </group>
          <group group_id="O2">
            <title>1xICS + LABA</title>
            <description>Dry-powder inhaler fluticasone + salmeterol combination 100 mcg/50 mcg bid (Advair Diskus®, GlaxoSmithKline)</description>
          </group>
          <group group_id="O3">
            <title>1xICS + LTRA</title>
            <description>Dry-powder inhaler fluticasone 100 mcg bid (Flovent Diskus®, GlaxoSmithKline) plus Montelukast 5 or 10 mg qd (Singulair®, Merck)</description>
          </group>
        </group_list>
        <measure>
          <title>Asthma Exacerbations</title>
          <description>An asthma exacerbation was defined as the administration of a course of oral/systemic prednisone for the treatment of asthma.</description>
          <population>Patients who completed the 16-week treatment period for the specific treatment (2xICS, 1xICS + LABA, or 1xICS + LTRA) within the three-way crossover design</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="165"/>
                <count group_id="O2" value="163"/>
                <count group_id="O3" value="161"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="49"/>
                    <measurement group_id="O2" value="35"/>
                    <measurement group_id="O3" value="37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>1 year</time_frame>
      <desc>does not differ from the clinicaltrials.gov definitions</desc>
      <group_list>
        <group group_id="E1">
          <title>All Participants</title>
          <description>All participants randomized to the six crossover sequences</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="182"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>tonsillectomy</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="182"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>appendicitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="182"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>behavioral problems</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="182"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>asthma exacerbation requirung hospitalization</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="182"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="22" subjects_at_risk="182"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>asthma exacerbation not requiring hospitalization</sub_title>
                <counts group_id="E1" events="22" subjects_affected="22" subjects_at_risk="182"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>The study was not designed or powered to evaluate the long-term safety of long-acting beta-agonists in children. The duration of the trial and its sample size preclude statements regarding long-term risks.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Vernon M. Chinchilli</name_or_title>
      <organization>Penn State Hershey College of Medicine</organization>
      <phone>717-531-4262</phone>
      <email>vchinchi@psu.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

